4D Molecular Therapeutics (NASDAQ:FDMT) Stock: Insider Scott Bizily Sells 1,635 Shares

Key Points

• Insider Scott Bizily sold 1,635 FDMT shares at an average price of $12.84, receiving $20,993.40. His remaining stake fell 15.95% to 8,617 shares.
• 4D Molecular Therapeutics shares recently traded at $13.10, with a market capitalization of approximately $723.6 million. The company reported a quarterly loss of $1.04 per share, slightly worse than analyst expectations, while revenue exceeded estimates.
• Institutional investors own 99.27% of the stock, and analysts maintain a “Moderate Buy” consensus with an average price target of $28.90, well above the recent trading price.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the stock in a transaction on Friday, October 16th. The stock was sold at an average price of $12.84, for a total transaction of $20,993.40. Following the sale, the insider owned 8,617 shares of the company's stock, valued at approximately $110,642.28. This represents a 15.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Scott Bizily also recently made the following trade(s):

• On Wednesday, September 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $13.65, for a total value of $22,317.75.
• On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $14.00, for a total transaction of $8,176.00.
• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total transaction of $19,620.00.
• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.20, for a total transaction of $19,947.00.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock traded up $0.81 on Tuesday, reaching $13.10. 718,021 shares of the stock were exchanged, compared to its average volume of 854,704. The firm has a market capitalization of $723.64 million, a PE ratio of -4.98 and a beta of 2.75. 4D Molecular Therapeutics, Inc. has a 1-year low of $6.96 and a 1-year high of $16.93. The business has a fifty day moving average price of $14.02 and a two-hundred day moving average price of $11.55. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). The business had revenue of $3.78 million during the quarter, compared to analysts' expectations of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. As a group, research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of large investors have recently bought and sold shares of the stock. Jupiter Topco LLC acquired a new position in 4D Molecular Therapeutics in the second quarter valued at $76,466,000. Janus Henderson Group PLC lifted its position in 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company's stock worth $48,868,000 after buying an additional 611,276 shares during the period. BlackRock Inc. acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter worth about $60,463,000. Trails Edge Capital Partners LP purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at about $29,631,296. Finally, Bank of America Corp DE purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at about $14,905,000. Institutional investors and hedge funds own 99.27% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on FDMT shares. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Bank of America raised their price objective on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a "buy" rating in a research note on Tuesday, September 29th. B. Riley Financial reissued a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Cantor Fitzgerald raised shares of 4D Molecular Therapeutics from a "neutral" rating to an "overweight" rating and set a $20.00 price objective on the stock in a report on Monday, September 14th. Finally, The Goldman Sachs Group restated a "buy" rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $28.90.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.